FDA's "least burdensome" guidance disappoints industry
This article was originally published in Clinica
Device companies were surprised and disappointed to learn last week that the FDA's much-anticipated guidance covering the "least burdensome" path to win product approval will be more narrow in scope than had been envisaged.
You may also be interested in...
By establishing a dedicated consumer healthcare subsidiary, Norgine is hoping it can grow its $200m-plus Movicol laxative brand and take advantage of M&A opportunities in the OTC market.
The AAM has insisted that the US Supreme Court should uphold the inter partes review framework, in an amicus brief filed as part of litigation that potentially threatens hundreds of IPR decisions.
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.